4Q-25 Quarterly Results 4Q-25 Revenue of $642M, 0% y/y 4Q-25 Net loss per share of $(0.14)(1) 4Q-25 Adj. EBITDA(2) of $83.8M, 12% y/y FY-26 Revenue outlook range of $2,470M to $2,587M Cautionary Note 2 • This presentation contains, and the officers of Teladoc Health, Inc. (the "Company" or "Teladoc Health") may make, "forward-looking" statements that are based on management's beliefs and assumptions and on information currently available to management. These forward-looking statements include, without limit ...

远程医疗平台Hims & Hers Health最新季度销售额上升，该公司持续扩充治疗项目范围，订阅用户数量 也有所增长。 Dudum表示，GLP‑1类药物确实为业务增长提供了显著助力，但这类药物只是其全球化消费平台中单一 领域的单一疗法，而随着持续投入，该平台正变得更加强健、多元。 他称，Hims & Hers仅有一小部分订阅用户使用复方GLP‑1类药物，这表明平台的影响力远不止于减重 领域。 他补充道，尽管并非所有新业务都能达到减重业务的增长速度，但凭借超级碗广告后用户接受度的快速 提升，公司有信心睾酮治疗、更年期护理及检测服务业务在不久的将来年营收均突破1亿美元。 "这三大新业务板块不只是新增服务，更是我们与客户建立更深度联结、创造更多价值的起点。" 尽管这家远程医疗平台预计今年增长势头将延续，但其第一季度业绩指引低于华尔街预期。 截至当日收盘，其股价在过去一年累计下跌69.8%。 这份财报发布之际，Hims & Hers正面临诺和诺德提起的诉讼，后者要求禁止该公司销售其减重药物的 仿制品。诺和诺德指控Hims & Hers侵犯司美格鲁肽相关专利，而Hims & Hers则批评该诉讼是在打压平 价药物选 ...

Financial Data and Key Metrics Changes - Total revenue for 2025 was $249.3 million, with subscription revenue representing 53% of total revenue, up from 45% in 2024 [12][13] - In Q4 2025, total revenue was $55.3 million, a 22.1% year-over-year decline, with subscription revenue at $28.8 million, down 22% year-over-year [13][14] - Adjusted EBITDA for Q4 was a loss of $10.3 million, an improvement from a loss of $12.7 million in Q3 2025 and a 55% improvement from $22.8 million in Q4 2024 [16] - Net loss for Q4 was $25.2 million, compared to $30.7 million in Q3, representing a 43.5% improvement year-over-year [16] Business Line Data and Key Metrics Changes - Amwell Medical Group (AMG) visit revenue was $23.7 million in Q4, down 18.7% year-over-year, reflecting the sale of APC and remaining churn from 2024 [14] - Paid AMG visits were flat at approximately 340,000 in Q4, while total platform visits were 1 million, down 28.4% year-over-year from 1.4 million visits in Q4 2024 [14] Market Data and Key Metrics Changes - The healthcare landscape is shifting towards operational efficiency, with payers and health systems pursuing platform consolidation and automation [3][4] - The Medicare population is aging, pharmacy costs are surging, and clinician shortages are worsening, creating a demand for technology-enabled care [4][5] Company Strategy and Development Direction - The company has focused exclusively on offering the best tech platform in the market, transitioning from a telehealth provider to a trusted enterprise infrastructure [9][10] - The strategy includes divesting non-core activities and restructuring to reduce costs, with a goal of cash flow breakeven from operations in Q4 2026 [10][11] - The company aims to leverage AI to enhance patient experience and improve operational efficiencies [11][18] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about achieving cash flow breakeven in Q4 2026, supported by a strong recurring revenue base and healthy cash reserves [11][17] - The company anticipates continued demand for its platform as AI-driven clinical programs grow and payers seek efficient infrastructure [19][28] Other Important Information - The company reported cash burn of approximately $19 million in Q4, ending the year with about $182 million in cash and marketable securities, and no debt [16][17] - For 2026, the company expects revenue in the range of $195 million to $205 million, with adjusted EBITDA losses between $24 million and $18 million [17][18] Q&A Session Summary Question: Thoughts on existing client contracts and government opportunities - Management noted that most contracts signed in 2025 were renewals, with fewer open renewals in 2026, except for the DHA renewal expected in summer [21][22] Question: Impact of new AI companies and trends on healthcare - Management is optimistic about AI's impact on healthcare, emphasizing the need for a consistent, regulated infrastructure to integrate multiple AI programs [24][26][28] Question: Headwinds and tailwinds for 2026 guidance - Tailwinds include earlier adoption of technology-enabled platforms, while headwinds involve the upcoming DHA renewal [31][33] Question: Details on DHA revenue step down and potential recovery - Management confirmed a step down in DHA revenue due to the elimination of certain programs but expressed confidence in renewing the contract and potentially adding those programs back [34][36] Question: Growth potential and market focus for 2026 - Management highlighted the strong secular trend towards technology-enabled care and the potential for same-store growth, particularly in the government sector [40][42][44]

Group 1 - The Asian Development Bank (ADB) forecasts a 4.6% economic growth for developing economies in the Asia-Pacific region by 2026, an increase of 0.1 percentage points from previous estimates, supported by stable economic fundamentals and a favorable investment environment [1] - In East Asia, economic growth forecasts for 2025 and 2026 have been raised to 4.6% and 4.1% respectively, with overall inflation remaining moderate [1] - The report highlights strong export performance in high-tech and innovative products from China, particularly in electric vehicles, photovoltaic products, and lithium batteries, contributing to high-quality economic development in the Asia-Pacific region [1] Group 2 - Southeast Asia is projected to see economic growth of 4.5% in 2025 and 4.4% in 2026, with countries like Indonesia, Malaysia, Singapore, and Vietnam showing strong growth, particularly in the third quarter of 2025 [1] - The tourism sector is rebounding quickly, with the Asia-Pacific region expected to receive 331 million international visitors in 2025, a 6% increase year-on-year, providing significant support for regional economic growth [2] - The digital economy is becoming a new growth driver for Southeast Asian countries, with Malaysia aiming to increase the digital economy's share of GDP to 25.5% by 2030, and Indonesia focusing on digital finance with over 56 million users accessing QR payment systems [4] Group 3 - The Regional Comprehensive Economic Partnership (RCEP) has attracted over 30% of global foreign direct investment, enhancing regional cooperation in areas like digital economy and green development [3] - The World Trade Organization has lowered the global goods trade growth forecast for 2026 to 0.5%, indicating challenges posed by unilateralism and protectionism affecting export-oriented economies in the Asia-Pacific region [3] - ADB emphasizes that developing economies in the Asia-Pacific are implementing policy measures to stabilize economic performance, with a focus on digital transformation and technological innovation to enhance growth resilience [4]

消息面上，远程医疗企业Hims & Hers Health宣布下架售价49美元的仿制减肥药。Hims & Hers于上周四 宣布推出该仿制减肥药，其售价较诺和诺德的Wegovy便宜约100美元。随后，诺和诺德发声明称，非法 Wegovy复方制剂风险巨大，将对Hims&Hers采取法律行动；美国食品药品监督管理局亦对其发出警 告。Hims & Hers表示，自从在平台上推出仿制减肥药司美格鲁肽药丸以来，公司已与整个行业的利益 持份者进行建设性的对话，目前已决定停止提供相关的治疗。(格隆汇) 诺和诺德(NVO.US)盘前涨6.6%，报50.79美元。Hims & Hers Health(HIMS.US)盘前跌近14%，报19.81美 元。 ...

Core Viewpoint - Hims & Hers has decided to withdraw its generic weight loss drug from the market following legal threats from Novo Nordisk and the FDA's announcement of potential legal action against the company [2][6]. Group 1: Product Withdrawal - Hims & Hers announced the withdrawal of its generic drug containing semaglutide, which was initially priced at $49 for the first month, significantly lower than Novo Nordisk's original product priced about $100 higher [2][6]. - The company stated that it has engaged in constructive communication with industry stakeholders since the launch of the semaglutide formulation [2][6]. Group 2: Legal Threats - Novo Nordisk threatened legal action against Hims & Hers, accusing the company of "illegally compounding drugs in bulk" and misleading the public with its generic GLP-1 product [2][6]. - The FDA plans to take legal action against Hims & Hers, which includes restricting access to the drug's raw materials and referring the case to the Department of Justice [2][6]. Group 3: Company Response - Hims & Hers responded by asserting its commitment to consumer safety and compliance with current laws and regulations [3][7]. - The company had planned to air an advertisement during the Super Bowl, highlighting the health gap in America, but made the decision to withdraw the drug just before the event [3][7].

这一价格远低于诺和诺德在其直连消费者的官网诺和关怀上的定价 —— 该平台上，维格卫起始剂量的 售价为 149 美元。 来源：环球市场播报 作者：埃尔莎・奥伦 这张图片为示意图，智能手机屏幕上显示着 Hims & Hers 健康公司的品牌标识。 受诺和诺德发出法律威胁影响，远程医疗企业 Hims & Hers 的股价在本周五早盘交易中走低。 这家线上远程医疗公司于周四宣布，计划推出诺和诺德减肥药丸的平价仿制品，此举直接引发诺和诺德 采取法律行动。 消息传出后，Hims 的股价在周四的交易中一度飙升 15%，但在诺和诺德指认该行为 "涉嫌违法" 后，股 价迅速回吐涨幅，最终收跌 3.8%，创 12 个月新低；本周五早盘交易中，其股价再度下跌 6.5%。 Hims 方面表示，将推出一款维格卫同款减肥药丸，其有效成分与原研药一致，均为司美格鲁肽。用户 订阅后，首月用药价格低至 49 美元，首月过后，价格将上调至 99 美元。 与此同时，巴克莱银行分析师詹姆斯・戈登认为，这款定价 49 美元的维格卫仿制品，成为诺和诺德面 临的 "新隐患"。 他补充道："尽管这类复合仿制药短期内可能吸引对价格敏感的患者，但该类产品的监管 ...

Core Viewpoint - Hims & Hers Health is set to offer a compound formulation of Novo Nordisk's weight loss drug Wegovy at a significantly lower price, leading to a notable increase in its stock price while impacting Novo Nordisk negatively [1] Group 1: Company Developments - Hims & Hers Health shares surged over 16% in pre-market trading following the announcement of the new compound formulation [1] - The compound formulation will be priced at $49 per month, which is approximately $100 cheaper than the brand-name drug Wegovy [1] - Patients opting for a five-month subscription will pay a one-time lower fee, followed by monthly payments of $99, compared to Novo Nordisk's $199 [1] Group 2: Market Reactions - Novo Nordisk's stock fell over 6% in response to the news regarding Hims & Hers Health's new offering [1] - Eli Lilly's shares also experienced a decline of over 4%, indicating a broader market reaction to the competitive pricing in the weight loss drug sector [1]

Group 1 - The company formerly known as 财讯传媒集团有限公司 has officially changed its name to BFB Health Limited, with the Chinese stock abbreviation updated to BFB HEALTH, while the stock code remains unchanged [1] - BFB HEALTH will focus on the remote medical health management sector as a publicly listed company in Hong Kong [1] - The company plans to allocate 50% of its secondary market financing for AI upgrades in the health industry and new drug development, while the other 50% will be used for product iteration, brand building, and upgrading intelligent production lines [1] Group 2 - BFB HEALTH is a private enterprise based in Bozhou, Anhui Province, leveraging the region's rich traditional Chinese medicine resources and a well-established health industry cluster [1] - The company has evolved from a regional leader to a national remote medical service platform, achieving large-scale and standardized operations in remote medical services [1] - BFB HEALTH has developed a closed-loop model of "online diagnosis + health management + product services," aligning with the industry's development path of "Internet + healthcare" [1]

Core Insights - Hims & Hers Health Inc (NYSE:HIMS) shares have increased by 3.4%, trading at $30.60, despite a significant nine-month deficit of 47.3% [1] - The stock has faced downward pressure since December, with the 20-day moving average limiting any potential rallies [1] Options Activity - The company has gained attention for its weight-loss drug prescriptions, appearing on a list of S&P 400 names with high options volume, with 720,590 calls and 423,949 puts traded in the last 10 days [3] - The most active options contract was the January 16, 2026, 30-strike put [3] Market Sentiment - Options traders have shown increased bullish sentiment, reflected in HIMS' 50-day call/put volume ratio of 3.11, which is the highest compared to the past year [6] - The Schaeffer's Volatility Index (SVI) for HIMS is at 65%, ranking in the 7th percentile of annual readings, indicating low volatility expectations [7] - HIMS' Schaeffer's Volatility Scorecard (SVS) is 83 out of 100, suggesting that the stock has historically experienced higher volatility than what options pricing indicates [7]